Vitamin D Supplementation Decreases TGF-β1 Bioavailability in PCOS: A Randomized Placebo-Controlled Trial | Zendy

Mohamad Irani | Zendy; David B. Seifer | Zendy; Richard V. Grazi | Zendy; Nitasha Julka | Zendy; Devika Bhatt | Zendy; Bharati Kalgi | Zendy; Sara Irani | Zendy; Oded Tal | Zendy; Geralyn LambertMesserlian | Zendy; Reshef Tal | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Vitamin D Supplementation Decreases TGF-β1 Bioavailability in PCOS: A Randomized Placebo-Controlled Trial

Author(s) -

Mohamad Irani,

David B. Seifer,

Richard V. Grazi,

Nitasha Julka,

Devika Bhatt,

Bharati Kalgi,

Sara Irani,

Oded Tal,

Geralyn LambertMesserlian,

Reshef Tal

Publication year - 2015

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2015-2580

Subject(s) - medicine , polycystic ovary , endocrinology , placebo , dehydroepiandrosterone sulfate , vitamin d and neurology , randomized controlled trial , insulin resistance , hormone , insulin , androgen , alternative medicine , pathology

There is an abnormal increase in TGF-β1 bioavailability in women with polycystic ovary syndrome (PCOS), which might play a role in the pathophysiology of this syndrome. Vitamin D (VD) supplementation improves various clinical manifestations of PCOS and decreases TGF-β1 levels in several diseases including myelofibrosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research